Cell and Gene Therapy 2018
Copthorne Tara Hotel *London, UK Visit the Venue to read more
SMi introduces their inaugural conference; Cell and Gene Therapy, which takes place between the 9th and 11th October 2018.
Cell and gene therapeutics have revolutionised modern medicine and mark a new generation in biomedical and agricultural sciences. The latest developments in cell and gene therapies and specifically in gene editing technologies present unlimited research opportunities ranging from novel therapeutic tools to a potential revolution in the field of drug discovery.
This year event will be led by scientists and clinicians researching, developing and testing new treatments for genetically inherited and acquired diseases using gene delivery technology, stem cell manipulation and DNA repair techniques. The conference will cover all aspects of the subject, including biomedical science principles, molecular basis of disease, current and developing technologies and clinical applications.
Join our expert speaker panel at the Cell and Gene Therapy conference to ensure you do not miss out on the latest developments! Presenting new technologies, specific case studies, updates on GMP, MHRA regulatory guidelines, quality control and therapeutic applications of stem cells, pre-clinical and clinical trial design, advanced cell engineering technologies, commercialisation of ATMPs, global pricing, ethical overviews and many more.
R&D Rare Disease Unit Head, Chiesi Farmaceutici S.p.A. Diego Ardigo
Dr. Ardigò is an MD (Internal Medicine) and obtained his PhD at the University of Parma (Italy) and his post-doctoral fellowship at Stanford University (California, US). Before joining the industry, he worked at the University of Parma (Italy) in the field of cardiovascular and metabolic genomics and as free-lance consultant for other academic institutions. He joined Chiesi in 2010, where acted as Clinical Lead in the registration of the first stem cell therapy in EU and led the cross-company team (with uniQure BV) treating the first patient with a commercial gene therapy in EU. He is currently the Head of the R&D Rare Disease Unit in Chiesi and chairman of the Therapies Scientific Committee of IRDiRC (International Rare Diseases Research Consortium) and member of EBE-EFPIA ATMP Working Group. He is author of more than 40 indexed papers and speaker at international medical and industrial congresses.
Associate Director, AstraZeneca Emanuela Cuomo
Emanuela Cuomo is an Associate Director in the Discovery Biology department in Cambridge. She leads the Cell Biology team and co-leads the Precise genome editing discipline contributing to innovation in the CRISPR field. The Cell biology team generated cell models for target identification and validation for the Oncology disease area, including Immuno Oncology.
Emanuela is an expert in the study of cell cycle signaling in normal and cancer cells.
She obtained a PhD in biochemistry at the Institute of Cancer Research in London where she characterised a novel viral cyclin/CDK complex, its modulation by CDK inhibitors and its biological function in oncogenesis. Subsequently she joined UCL Cancer Institute in London in the Viral Oncogenesis team as a CR-UK postdoctoral fellow. There, she studied the interplay between the cellular DNA damage response and viral protein kinases.
Partner, Alira Health Fabio D'Agostino
Dr. Fabio D’Agostino brings extensive experience in cell and gene therapy to Alira Health. In 2013, he joined the Parenteral Drug Association (PDA) Cell and Gene Task Force (members include executives from GSK, Novartis, Lonza, Johnson & Johnson, Adaptimmune, Tigenix, Bluebird Bio) with the aim to develop a manufacturing control strategy for cell and gene based medicinal products. His areas of expertise also include Lean Six Sigma, process development and optimization, business development, technology evaluation.
Fabio started his career at the medical device company Sorin Group (now LivaNova) after a BSc and a MSc with honors in Biomedical Engineering from the Polytechnic University of Turin (Italy). Later, he moved to Newcastle (UK) to take an Engineering Doctorate in Biopharmaceutical Process Development at Newcastle University.
Group registrations not allowed
Accompanying persons not allowed
We don’t accept Online Abstracts
COPTHORNE TARA HOTEL
Scarsdale Place, Kensington, London, United Kingdom
The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.
The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.
+44 (0)20 7827 6000